1. Market Research
  2. > ICT Market Trends
Asia Pacific RNAi Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Molecule Type, Application, Route of Administration, and End User and Country

Asia Pacific RNAi Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Molecule Type, Application, Route of Administration, and End User and Country

  • October 2020
  • 133 pages
  • ID: 5989508
  • Format: PDF
  • The Insight Partners

Summary

Table of Contents

Search Inside

The Asia Pacific RNAi therapeutics market is expected to reach US$ 218.64 million by 2027 from US$ 107.63 million in 2019. The market is expected to grow at a CAGR of 9.3% from 2020 to 2027.

The RNAi therapeutics market is growing primarily due to increasing investments in RNAi therapies and rising prevalence of infectious diseases & chronic conditions in Asia Pacific.However, high cost of RNAi therapeutics is likely to restrain the growth of the market.

Additionally, significant number of pipeline candidates for strategic alliances and rising emphasis on RNA technologies are likely to fuel the growth of the RNAi therapeutics market during the forecast period.

RNAi refers to the interference RNA which is responsible for controlling and manipulating protein translation in the cell.These RNAi are used to silence particular genes which are responsible for diseases.

Currently, the awareness about RNAi is increasing extensively due to its ability to offer target specific mechanism, leading to superior treatment outcomes.The approach is widely utilized for drug development.

Increasing number of investments in RNAi therapy development coupled with growing prevalence of infectious diseases and chronic conditions are anticipated to drive the market during the forecast period.

According to the WHO, 79% of deaths in China are due to chronic diseases.Lifestyle changes stemming from rising wealth are behind much of the shift, with stroke, heart disease and lung and liver cancers supplanting lower respiratory diseases and neonatal disorders, according to a joint study by the Chinese Center for Disease Control and Prevention and the Institute for Health Metrics and Evaluation at the University of Washington in Seattle.

This has propelled the growth of healthcare systems. Extensive R&D activities are being conducted by government institutions and academic research centers to discover new drug delivery technologies and deal with the increasing number of patients suffering from infectious diseases (such as pneumonia, meningitis, food poisoning, and flu) and chronic conditions (such as cancer, diabetes, and cardiovascular conditions).

China has been the epicenter of the infectious disease throughout the history.For instance, in 2006, the five most frequently reported infectious diseases in China were tuberculosis, hepatitis B, dysentery, syphilis, and gonorrhea.

Also, in December 2019, in Wuhan, Hubei, China, COVID-19 was identified.This has resulted in a pandemic.

According to the Worldometer, 30.6 million people are infected with COVID-19 till date. These numbers show that the cases of infectious diseases, are increasing day by day.

Furthermore, cancer and diabetes are among the leading causes of mortality. For instance, there were 4.3 million new cancer cases and more than 2.8 million cancer deaths in China in 2015, with lung cancer being the most common cancer and the leading cause of cancer death in China. With increasing incidence and mortality, cancer is the leading cause of death in China and is a major public health issue. Also, approximately 1 out of 10 adults in China is suffering from diabetes. RNAi therapies have significant potential to provide promising treatment for such extensively increasing diseases. Thus, the staggering number of cases necessitates the need for superior treatments, which, in turn, bolsters the growth of the RNAi therapeutics market.
In 2019, the small interfering RNAs (siRNA) segment accounted for the highest share of the market.Growth of this segment is attributed to increasing preference for small interfering RNAs for drug development and growing number of research partnerships.

Furthermore, the microRNA (miRNA) segment is expected to register higher CAGR in the RNAi therapeutics market during the forecast period.

A few of the major secondary sources associated with the Asia Pacific RNAi therapeutics market report are World Health Organization (WHO), Chinese Center for Disease Control and Prevention, and World Population Prospects, among others.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

UK Tax Software Market Forecast to 2027 - COVID-19 Impact and Country Analysis by Product Type, Tax Type, Deployment Type, End-User, Industry Vertical

  • $ 3000
  • December 2020
  • 141 pages

The UK tax software market was valued at US$ 611.3 million in 2019 and is projected to reach US$ 1,331.3 million by 2027; it is expected to grow at a CAGR of 10.5% from 2020 to 2027. Digitalization has ...

  • United Kingdom
  • Cloud Computing
  • ICT
  • Industry analysis
  • General Government Tax Revenue
  • Telecom Revenue

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on